From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage

Immunobiology

Volumn 221, Issue 10, 2016, Pages 1046-1057

  Mastellos, Dimitrios C ^a,b   Reis, Edimara S ^a   Yancopoulou, Despina ^c   Hajishengallis, George ^d   Ricklin, Daniel ^a   Lambris, John D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^c Glyfada   (Greece)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

AMY 101; C3 convertase; Clinical efficacy; Complement dysregulation; Peptidic C3 inhibitors; Primate models

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; COMPLEMENT RECEPTOR; COMPLEMENT RECEPTOR 2; ECULIZUMAB; HYBRID PROTEIN; ORPHAN DRUG; PROTEIN VARIANT; UNCLASSIFIED DRUG; COMPLEMENT INHIBITOR; COMPSTATIN; CYCLOPEPTIDE;

COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; CONFORMATIONAL TRANSITION; GLOMERULOPATHY; HEMODIALYSIS; HUMAN; INFLAMMATION; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PERIODONTAL DISEASE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; THROMBOINFLAMMATION; TREND STUDY; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CLINICAL STUDY; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG MANUFACTURE; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PRECLINICAL STUDY; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME;

ANIMALS; CLINICAL STUDIES AS TOPIC; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT INACTIVATING AGENTS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOTHERAPY; ORPHAN DRUG PRODUCTION; PEPTIDES, CYCLIC; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME;

EID: 84977641685     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2016.06.013     Document Type: Review

References (98)

1. AMYNDAS Pharmaceuticals, 2016. Amyndas’ lead candidate AMY-101 receives orphan drug status from the FDA and the EMA for the treatment of C3 glomerulopathy. http://www.fiercepharma.com/pharma/amyndas%E2%80%99-lead-candidate-amy-101-receives-orphan-drug-status-from-fda-and-ema-for-treatment (accessed 14.04.16.).
2. Abe, T., Hosur, K.B., Hajishengallis, E., Reis, E.S., Ricklin, D., Lambris, J.D., Hajishengallis, G., Local complement-targeted intervention in periodontitis: proof-of-concept using a C5a receptor (CD88) antagonist. J. Immunol. 189 (2012), 5442–5448.
3. Alcon Research, 2013. A Multicenter, Proof-of-Concept Study of Intravitreal AL-78898A in Patients with Geograhic Atrophy (GA) associated with Age-Related Macular Degeneration (AMD). ClinicalTrials.gov, Identifier:NCT01603043.
4. Armitage, G.C., Classifying periodontal diseases—a long-standing dilemma. Periodontology 2000 30 (2002), 9–23.
5. Banda, N.K., Levitt, B., Glogowska, M.J., Thurman, J.M., Takahashi, K., Stahl, G.L., Tomlinson, S., Arend, W.P., Holers, V.M., Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice. J. Immunol. 183 (2009), 5928–5937.
6. Beikler, T., Flemmig, T.F., Oral biofilm-associated diseases: trends and implications for quality of life, systemic health and expenditures. Periodontology 2000 55 (2011), 87–103.
7. Bentall, A., Tyan, D.B., Sequeira, F., Everly, M.J., Gandhi, M.J., Cornell, L.D., Li, H., Henderson, N.A., Raghavaiah, S., Winters, J.L., Dean, P.G., Stegall, M.D., Antibody-mediated rejection despite inhibition of terminal complement. Transpl. Int. 27 (2014), 1235–1243.
8. Berentsen, S., Role of complement in autoimmune hemolytic anemia. Transfus. Med. Hemother. 42 (2015), 303–310.
9. Biglarnia, A.R., Nilsson, B., Nilsson, E.K., Tufveson, G., Nilsson, T., Larsson, E., Wadstrom, J., Desensitization with antigen-specific immunoadsorption interferes with complement in ABO-incompatible kidney transplantation. Transplantation 93 (2012), 87–92.
10. Chapple, I.L., Time to take periodontitis seriously. BMJ, 348, 2014, g2645.
11. Chen, S.S., Zhong, S., Xiang, Y., Li, J.H., Guo, H., Wang, W.Y., Xiong, Y.L., Li, X.C., Chen, S.S., Chen, X.P., Chen, G., Complement inhibition enables renal allograft accommodation and long-term engraftment in presensitized nonhuman primates. Am. J. Transplant. 11 (2011), 2057–2066.
12. Chen, Q., Wiesener, M., Eberhardt, H.U., Hartmann, A., Uzonyi, B., Kirschfink, M., Amann, K., Buettner, M., Goodship, T., Hugo, C., Skerka, C., Zipfel, P.F., Complement factor H-related hybrid protein deregulates complement in dense deposit disease. J. Clin. Invest. 124 (2014), 145–155.
13. Chi, Z.L., Yoshida, T., Lambris, J.D., Iwata, T., Suppression of drusen formation by compstatin a peptide inhibitor of complement C3 activation, on cynomolgus monkey with early-onset macular degeneration. Adv. Exp. Med. Biol. 703 (2010), 127–135.
14. Colombo, A.P., Bennet, S., Cotton, S.L., Goodson, J.M., Kent, R., Haffajee, A.D., Socransky, S.S., Hasturk, H., Van Dyke, T.E., Dewhirst, F.E., Paster, B.J., Impact of periodontal therapy on the subgingival microbiota of severe periodontitis: comparison between good responders and individuals with refractory periodontitis using the human oral microbe identification microarray. J. Periodontol. 83 (2012), 1279–1287.
15. Coulthard, L.G., Woodruff, T.M., Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth. J. Immunol. 194 (2015), 3542–3548.
16. Ekdahl, K.N., Lambris, J.D., Elwing, H., Ricklin, D., Nilsson, P.H., Teramura, Y., Nicholls, I.A., Nilsson, B., Innate immunity activation on biomaterial surfaces: a mechanistic model and coping strategies. Adv. Drug Deliv. Rev. 63 (2011), 1042–1050.
17. Ekdahl, K.N., Teramura, Y., Asif, S., Jonsson, N., Magnusson, P.U., Nilsson, B., Thromboinflammation in therapeutic medicine. Adv. Exp. Med. Biol. 865 (2015), 3–17.
18. Eke, P.I., Dye, B.A., Wei, L., Thornton-Evans, G.O., Genco, R.J., Prevalence of periodontitis in adults in the United States: 2009 and 2010. J. Dent. Res. 91 (2012), 914–920.
19. Fiane, A.E., Mollnes, T.E., Videm, V., Hovig, T., Høgåsen, K., Mellbye, O.J., Spruce, L., Moore, W.T., Sahu, A., Lambris, J.D., Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. Xenotransplantation 6 (1999), 52–65.
20. Fridkis-Hareli, M., Storek, M., Mazsaroff, I., Risitano, A.M., Lundberg, A.S., Horvath, C.J., Holers, V.M., Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood 118 (2011), 4705–4713.
21. Gale, D.P., de Jorge, E.G., Cook, H.T., Martinez-Barricarte, R., Hadjisavvas, A., McLean, A.G., Pusey, C.D., Pierides, A., Kyriacou, K., Athanasiou, Y., Voskarides, K., Deltas, C., Palmer, A., Fremeaux-Bacchi, V., de Cordoba, S.R., Maxwell, P.H., Pickering, M.C., Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 376 (2010), 794–801.
22. Goto, M., Tjernberg, J., Dufrane, D., Elgue, G., Brandhorst, D., Ekdahl, K.N., Brandhorst, H., Wennberg, L., Kurokawa, Y., Satomi, S., Lambris, J.D., Gianello, P., Korsgren, O., Nilsson, B., Dissecting the instant blood-mediated inflammatory reaction in islet xenotransplantation. Xenotransplantation 15 (2008), 225–234.
23. Gros, P., Milder, F.J., Janssen, B.J., Complement driven by conformational changes. Nat. Rev. Immunol. 8 (2008), 48–58.
24. Hajishengallis, G., Hajishengallis, E., Kajikawa, T., Wang, B., Yancopoulou, D., Ricklin, D., Lambris, J.D., Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application. Semin. Immunol., 2016 (in press).
25. Hajishengallis, G., Immunomicrobial pathogenesis of periodontitis: keystones pathobionts, and host response. Trends Immunol. 35 (2014), 3–11.
26. Hajishengallis, G., The inflammophilic character of the periodontitis-associated microbiota. Mol. Oral Microbiol. 29 (2014), 248–257.
27. Hajishengallis, G., Periodontitis: from microbial immune subversion to systemic inflammation. Nat. Rev. Immunol. 15 (2015), 30–44.
28. Harboe, M., Ulvund, G., Vien, L., Fung, M., Mollnes, T.E., The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin. Exp. Immunol. 138 (2004), 439–446.
29. Harboe, M., Garred, P., Karlstrøm, E., Lindstad, J.K., Stahl, G.L., Mollnes, T.E., The down-stream effects of mannan-induced lectin complement pathway activation depend quantitatively on alternative pathway amplification. Mol. Immunol. 47 (2009), 373–380.
30. Harris, C.L., Heurich, M., Rodriguez de, C.S., Morgan, B.P., The complotype: dictating risk for inflammation and infection. Trends Immunol. 33 (2012), 513–521.
31. Hebecker, M., Alba-Dominguez, M., Roumenina, L.T., Reuter, S., Hyvarinen, S., Dragon-Durey, M.A., Jokiranta, T.S., Sanchez-Corral, P., Jozsi, M., An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H. J. Immunol. 191 (2013), 912–921.
32. Holers, V.M., Rohrer, B., Tomlinson, S., CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation. Adv. Exp. Med. Biol. 735 (2013), 137–154.
33. Huang, Y., Reis, E.S., Knerr, P.J., van der Donk, W.A., Ricklin, D., Lambris, J.D., Conjugation to albumin-binding molecule tags as a strategy to improve both efficacy and pharmacokinetic properties of the complement inhibitor compstatin. ChemMedChem 9 (2014), 2223–2226.
34. Huber-Lang, M., Sarma, J.V., Zetoune, F.S., Rittirsch, D., Neff, T.A., McGuire, S.R., Lambris, J.D., Warner, R.L., Flierl, M.A., Hoesel, L.M., Gebhard, F., Younger, J.G., Drouin, S.M., Wetsel, R.A., Ward, P.A., Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 12 (2006), 682–687.
35. Janssen, B.J., Halff, E.F., Lambris, J.D., Gros, P., Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. J. Biol. Chem. 282 (2007), 29241–29247.
36. Katschke, K.J. Jr., Wu, P., Ganesan, R., Kelley, R.F., Mathieu, M.A., Hass, P.E., Murray, J., Kirchhofer, D., Wiesmann, C., van Lookeren, C.M., Inhibiting alternative pathway complement activation by targeting the factor D exosite. J. Biol. Chem. 287 (2012), 12886–12892.
37. Kolev, M., Friec, G.L., Kemper, C., Complement—tapping into new sites and effector systems. Nat. Rev. Immunol. 14 (2014), 811–820.
38. Kourtzelis, I., Markiewski, M.M., Doumas, M., Rafail, S., Kambas, K., Mitroulis, I., Panagoutsos, S., Passadakis, P., Vargemezis, V., Magotti, P., Qu, H., Mollnes, T.E., Ritis, K., Lambris, J.D., Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood 116 (2010), 631–639.
39. Kourtzelis, I., Ferreira, A., Mitroulis, I., Ricklin, D., Bornstein, S.R., Waskow, C., Lambris, J.D., Chavakis, T., Complement inhibition in a xenogeneic model of interactions between human whole blood and porcine endothelium. Horm. Metab. Res. 47 (2015), 36–42.
40. Kourtzelis, I., Magnusson, P.U., Kotlabova, K., Lambris, J.D., Chavakis, T., Regulation of instant blood mediated inflammatory reaction (IBMIR) in pancreatic islet xeno-transplantation: points for therapeutic interventions. Adv. Exp. Med. Biol. 865 (2015), 171–188.
41. Lin, Z., Schmidt, C.Q., Koutsogiannaki, S., Ricci, P., Risitano, A.M., Lambris, J.D., Ricklin, D., Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria. Blood 126 (2015), 891–894.
42. Maekawa, T., Abe, T., Hajishengallis, E., Hosur, K.B., Deangelis, R.A., Ricklin, D., Lambris, J.D., Hajishengallis, G., Genetic and intervention studies implicating complement c3 as a major target for the treatment of periodontitis. J. Immunol. 192 (2014), 6020–6027.
43. Maekawa, T., Briones, R.A., Resuello, R.R., Tuplano, J.V., Hajishengallis, E., Kajikawa, T., Koutsogiannaki, S., Garcia, C.A., Ricklin, D., Lambris, J.D., Hajishengallis, G., Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3. J. Clin. Periodontol. 43 (2016), 238–249.
44. Mastellos, D.C., Ricklin, D., Yancopoulou, D., Risitano, A., Lambris, J.D., Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. Expert Rev. Hematol. 7 (2014), 583–598.
45. Mastellos, D.C., Yancopoulou, D., Kokkinos, P., Huber-Lang, M., Hajishengallis, G., Biglarnia, A.R., Lupu, F., Nilsson, B., Risitano, A.M., Ricklin, D., Lambris, J.D., Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur. J. Clin. Invest. 45 (2015), 423–440.
46. Morgan, B.P., Harris, C.L., Complement: a target for therapy in inflammatory and degenerative diseases. Nat. Rev. Drug Discov. 14 (2015), 857–877.
47. Nishimura, J., Yamamoto, M., Hayashi, S., Ohyashiki, K., Ando, K., Brodsky, A.L., Noji, H., Kitamura, K., Eto, T., Takahashi, T., Masuko, M., Matsumoto, T., Wano, Y., Shichishima, T., Shibayama, H., Hase, M., Li, L., Johnson, K., Lazarowski, A., Tamburini, P., Inazawa, J., Kinoshita, T., Kanakura, Y., Genetic variants in C5 and poor response to eculizumab. N. Engl. J. Med. 370 (2014), 632–639.
48. Parker, C., Omine, M., Richards, S., Nishimura, J., Bessler, M., Ware, R., Hillmen, P., Luzzatto, L., Young, N., Kinoshita, T., Rosse, W., Socie, G., Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 106 (2005), 3699–3709.
49. Pickering, M.C., D'Agati, V.D., Nester, C.M., Smith, R.J., Haas, M., Appel, G.B., Alpers, C.E., Bajema, I.M., Bedrosian, C., Braun, M., Doyle, M., Fakhouri, F., Fervenza, F.C., Fogo, A.B., Fremeaux-Bacchi, V., Gale, D.P., Goicoechea de, J.E., Griffin, G., Harris, C.L., Holers, V.M., Johnson, S., Lavin, P.J., Medjeral-Thomas, N., Paul, M.B., Nast, C.C., Noel, L.H., Peters, D.K., Rodriguez de, C.S., Servais, A., Sethi, S., Song, W.C., Tamburini, P., Thurman, J.M., Zavros, M., Cook, H.T., C3 glomerulopathy: consensus report. Kidney Int. 84 (2013), 1079–1089.
50. Qu, H., Ricklin, D., Lambris, J.D., Recent developments in low molecular weight complement inhibitors. Mol. Immunol. 47 (2009), 185–195.
51. Qu, H., Ricklin, D., Bai, H., Chen, H., Reis, E.S., Maciejewski, M., Tzekou, A., Deangelis, R.A., Resuello, R.R., Lupu, F., Barlow, P.N., Lambris, J.D., New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology 218 (2013), 496–505.
52. Ra Pharmaceuticals, 2016. Ra Pharmaceuticals Announces Initiation of First-in-Human Clinical Trial of Novel Complement C5 Inhibitor. http://www.rapharma.com/global/downloads/Ra-Pharma-PR-120115-Phase-1-ASH-FINAL.pdf (accessed 14.04.16.).
53. Rams, T.E., Degener, J.E., van Winkelhoff, A.J., Antibiotic resistance in human chronic periodontitis microbiota. J. Periodontol. 85 (2014), 160–169.
54. Regillo, C.D., Yaspan, B.L., Li, Z., Dressen, A., van Lookeren Campagne, M., Graham, R., Beres, T., Le, K., Henry, E., Ho, C., Strauss, E.C. On behalf of the MAHALO Study Investigators, 2013. Lampalizumab (Anti-factor D) in Patients with Geographic Atrophy: the MAHALO Phase II Results. In: 117th Annual AAO meeting. 117th Annual AAO meeting, New Orleans, LA.
55. Reis, S., Falcao, D.A., Isaac, L., Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H. Scand. J. Immunol. 63 (2006), 155–168.
56. Reis, E.S., Deangelis, R.A., Chen, H., Resuello, R.R., Ricklin, D., Lambris, J.D., Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters. Immunobiology 220 (2014), 476–482.
57. Reis, E.S., Mastellos, D.C., Yancopoulou, D., Risitano, A.M., Ricklin, D., Lambris, J.D., Applying complement therapeutics to rare diseases. Clin. Immunol. 161 (2015), 225–240.
58. Ricklin, D., Lambris, J.D., Compstatin: a complement inhibitor on its way to clinical application. Adv. Exp. Med. Biol. 632 (2008), 273–292.
59. Ricklin, D., Lambris, J.D., Complement in immune and inflammatory disorders: pathophysiological mechanisms. J. Immunol. 190 (2013), 3831–3838.
60. Ricklin, D., Lambris, J.D., Complement in immune and inflammatory disorders: therapeutic interventions. J. Immunol. 190 (2013), 3839–3847.
61. Ricklin, D., Lambris, J.D., Progress and trends in complement therapeutics. Adv. Exp. Med. Biol. 735 (2013), 1–22.
62. Ricklin, D., Lambris, J.D., Therapeutic control of complement activation at the level of the central component C3. Immunobiology 221 (2016), 740–746.
63. Ricklin, D., Lambris, J.D., New milestones ahead in complement-targeted therapy. Semin. Immunol., 2016 (in press).
64. Ricklin, D., Hajishengallis, G., Yang, K., Lambris, J.D., Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11 (2010), 785–797.
65. Risitano, A.M., Notaro, R., Marando, L., Serio, B., Ranaldi, D., Seneca, E., Ricci, P., Alfinito, F., Camera, A., Gianfaldoni, G., Amendola, A., Boschetti, C., Di, B.E., Fratellanza, G., Barbano, F., Rodeghiero, F., Zanella, A., Iori, A.P., Selleri, C., Luzzatto, L., Rotoli, B., Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 113 (2009), 4094–4100.
66. Risitano, A.M., Notaro, R., Luzzatto, L., Hill, A., Kelly, R., Hillmen, P., Paroxysmal nocturnal hemoglobinuria–hemolysis before and after eculizumab. N. Engl. J. Med. 363 (2010), 2270–2272.
67. Risitano, A.M., Notaro, R., Pascariello, C., Sica, M., Del, V.L., Horvath, C.J., Fridkis-Hareli, M., Selleri, C., Lindorfer, M.A., Taylor, R.P., Luzzatto, L., Holers, V.M., The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood 119 (2012), 6307–6316.
68. Risitano, A.M., Ricklin, D., Huang, Y., Reis, E.S., Chen, H., Ricci, P., Lin, Z., Pascariello, C., Raia, M., Sica, M., Del, V.L., Pane, F., Lupu, F., Notaro, R., Resuello, R.R., Deangelis, R.A., Lambris, J.D., Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood 123 (2014), 2094–2101.
69. Risitano, A.M., Storek, M., Sahelijo, L., Doyle, M., Dai, Y., Weitz, I.C., Marsh, J.C.W., Elebute, M.O., O'Connell, C.L., Kulasekararaj, A.G., Ramsingh, G., Marotta, S., Hellmann, A., Lundberg, A.S., 2015. Safety and Pharmacokinetics of the Complement Inhibitor TT30 in a Phase I Trial for Untreated PNH Patients. In: ASH 57th Annual Meeting & Exposition, Orlando, FL.
70. Risitano, A.M., Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders. Immunobiology 217 (2012), 1080–1087.
71. Risitano, A.M., Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies. Adv. Exp. Med. Biol. 735 (2013), 155–172.
72. Rondelli, T., Risitano, A.M., Peffault de, L.R., Sica, M., Peruzzi, B., Ricci, P., Barcellini, W., Iori, A.P., Boschetti, C., Valle, V., Fremeaux-Bacchi, V., De, A.M., Socie, G., Luzzatto, L., Notaro, R., Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria. Haematologica 99 (2014), 262–266.
73. Rother, R.P., Rollins, S.A., Mojcik, C.F., Brodsky, R.A., Bell, L., Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol. 25 (2007), 1256–1264.
74. Roversi, P., Lissina, O., Johnson, S., Ahmat, N., Paesen, G.C., Ploss, K., Boland, W., Nunn, M.A., Lea, S.M., The structure of OMCI, a novel lipocalin inhibitor of the complement system. J. Mol. Biol. 369 (2007), 784–793.
75. Sacks, S.H., Zhou, W., The role of complement in the early immune response to transplantation. Nat. Rev. Immunol. 12 (2012), 431–442.
76. Sahu, A., Kay, B.K., Lambris, J.D., Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J. Immunol. 157 (1996), 884–891.
77. Sahu, A., Soulika, A.M., Morikis, D., Spruce, L., Moore, W.T., Lambris, J.D., Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin. J. Immunol. 165 (2000), 2491–2499.
78. Sahu, A., Morikis, D., Lambris, J.D., Compstatin a peptide inhibitor of complement, exhibits species-specific binding to complement component C3. Mol. Immunol. 39 (2003), 557–566.
79. Santoro, D., Satta, E., Messina, S., Costantino, G., Savica, V., Bellinghieri, G., Pain in end-stage renal disease: a frequent and neglected clinical problem. Clin. Nephrol. 79:Suppl. 1 (2013), S2–11.
80. Schmidt, C.Q., Bai, H., Lin, Z., Risitano, A.M., Barlow, P.N., Ricklin, D., Lambris, J.D., Rational engineering of a minimized immune inhibitor with unique triple-targeting properties. J. Immunol. 190 (2013), 5712–5721.
81. Schmidt, C.Q., Harder, M.J., Nichols, E.M., Hebecker, M., Anliker, M., Hochsmann, B., Simmet, T., Csincsi, A.I., Uzonyi, B., Pappworth, I.Y., Ricklin, D., Lambris, J.D., Schrezenmeier, H., Jozsi, M., Marchbank, K.J., Selectivity of C3-opsonin targeted complement inhibitors: a distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. Immunobiology 221 (2016), 503–511.
82. Schramm, E.C., Clark, S.J., Triebwasser, M.P., Raychaudhuri, S., Seddon, J.M., Atkinson, J.P., Genetic variants in the complement system predisposing to age-related macular degeneration: a review. Mol. Immunol. 61 (2014), 118–125.
83. Servais, A., Noel, L.H., Roumenina, L.T., Le, Q.M., Ngo, S., Dragon-Durey, M.A., Macher, M.A., Zuber, J., Karras, A., Provot, F., Moulin, B., Grunfeld, J.P., Niaudet, P., Lesavre, P., Fremeaux-Bacchi, V., Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 82 (2012), 454–464.
84. Sethi, S., Fervenza, F.C., Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS). Semin. Thromb. Hemost. 40 (2014), 416–421.
85. Silasi-Mansat, R., Zhu, H., Popescu, N.I., Peer, G., Sfyroera, G., Magotti, P., Ivanciu, L., Lupu, C., Mollnes, T.E., Taylor, F.B., Kinasewitz, G., Lambris, J.D., Lupu, F., Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood 116 (2010), 1002–1010.
86. Smith, R.J., Alexander, J., Barlow, P.N., Botto, M., Cassavant, T.L., Cook, H.T., de Cordoba, S.R., Hageman, G.S., Jokiranta, T.S., Kimberling, W.J., Lambris, J.D., Lanning, L.D., Levidiotis, V., Licht, C., Lutz, H.U., Meri, S., Pickering, M.C., Quigg, R.J., Rops, A.L., Salant, D.J., Sethi, S., Thurman, J.M., Tully, H.F., Tully, S.P., van d, V., Walker, P.D., Wurzner, R., Zipfel, P.F., New approaches to the treatment of dense deposit disease. J. Am. Soc. Nephrol. 18 (2007), 2447–2456.
87. Sprong, T., Brandtzaeg, P., Fung, M., Pharo, A.M., Høiby, E.A., Michaelsen, T.E., Aase, A., van der Meer, J.W., van Deuren, M., Mollnes, T.E., Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis. Blood 102 (2003), 3702–3710.
88. Stegall, M.D., Chedid, M.F., Cornell, L.D., The role of complement in antibody-mediated rejection in kidney transplantation. Nat. Rev. Nephrol. 8 (2012), 670–678.
89. Swedish Orphan Biovitrum, 2016. Safety and Tolerability of SOBI002 in Healthy Volunteers Following Single and Repeated Administration. https://clinicaltrials.gov/ct2/show/NCT02083666?term=SOBI&rank=1.
90. Takeda, J., Miyata, T., Kawagoe, K., Iida, Y., Endo, Y., Fujita, T., Takahashi, M., Kitani, T., Kinoshita, T., Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 73 (1993), 703–711.
91. Teramura, Y., Asif, S., Ekdahl, K.N., Nilsson, B., Cell surface engineering for regulation of immune reactions in cell therapy. Adv. Exp. Med. Biol. 865 (2015), 189–209.
92. Wang, J., Wang, L., Xiang, Y., Ricklin, D., Lambris, J.D., Chen, G., Using an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40. Clin. Immunol. 162 (2016), 37–44.
93. Woodruff, T.M., Nandakumar, K.S., Tedesco, F., Inhibiting the C5-C5a receptor axis. Mol. Immunol. 48 (2011), 1631–1642.
94. Wu, Y.Q., Qu, H., Sfyroera, G., Tzekou, A., Kay, B.K., Nilsson, B., Nilsson, E.K., Ricklin, D., Lambris, J.D., Protection of nonself surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicine. J. Immunol. 186 (2011), 4269–4277.
95. Wu, M.C., Brennan, F.H., Lynch, J.P., Mantovani, S., Phipps, S., Wetsel, R.A., Ruitenberg, M.J., Taylor, S.M., Woodruff, T.M., The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries by inhibiting neutrophil mobilization. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 9439–9444.
96. Xiao, X., Pickering, M.C., Smith, R.J., C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis. Semin. Thromb. Hemost. 40 (2014), 465–471.
97. Zhang, Y., Nester, C.M., Holanda, D.G., Marsh, H.C., Hammond, R.A., Thomas, L.J., Meyer, N.C., Hunsicker, L.G., Sethi, S., Smith, R.J., Soluble CR1 therapy improves complement regulation in C3 glomerulopathy. J. Am. Soc. Nephrol. 24 (2013), 1820–1829.
98. Zhang, Y., Shao, D., Ricklin, D., Hilkin, B.M., Nester, C.M., Lambris, J.D., Smith, R.J., Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy. Immunobiology 220 (2015), 993–998.